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Current Concepts in Hemodialysis Vascular
Access Infections
Lalathaksha Kumbar and Jerry Yee
Infection-related causes are second only to cardiovascular events for mortality among end-stage renal disease patients. This
review will provide an overview of hemodialysis catheter-, graft-, and fistula-related infections with emphasis on diagnosis
and management in specific settings. Use of catheters at the initiation of dialysis has remained unchanged at 80%. Of all
access-related bloodstream infections (BSIs), 70% occur in patients with catheters. The risk factors for BSIs in tunneled, cuffed
catheters include the duration of the catheter, past catheter-related bacteremia, left-sided internal jugular vein catheters, hypoalbuminemia, and immunosuppression. Surprisingly, human immunodeficiency virus infection has not been associated with a
higher risk of catheter-related bacteremia. Catheter-related bloodstream infection is a clinical definition that requires specific
laboratory testing to identify the catheter as the source of the BSI. A central line–associated bloodstream infection is a primary
BSI in a patient who had a catheter within the 48-h period before the development of the BSI with no other identifiable source.
Guidewire exchange of catheter is a viable alternative in select patients to aid in preserving venous access sites. Catheter lock
therapy can decrease infectious complications and mortality. Arteriovenous graft infections are prevalent with significant
morbidity. Studies evaluating the impact of stent use in infection risks of the arteriovenous graft are sorely needed.
Q 2018 by the National Kidney Foundation, Inc. All rights reserved.
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A

n estimated 30 million people in the United States
have chronic kidney disease (CKD) with nearly
500,000 undergoing maintenance hemodialysis (HD).1
The cost to care for patients with end-stage renal disease
(ESRD) was approximately $34 billion in 20151 and every
day in the hospital is expected to raise patient care expense
by 0.8%.2 Risk of hospitalization in patients with CKD is
almost triple that of the patient without CKD (614 vs 227
hospitalizations/1000 at-risk patient-years).1 On average,
an ESRD patient is admitted to the hospital about twice
a year and has an extremely high 30-day readmission
rate of 34.6%. Cardiovascular events and infection
continue to be the leading causes of hospitalization,
although marked improvements have been noted in the
rates of hospitalization. Vascular access infection accounts
for nearly 28% of all infections affecting ESRD hospitalizations. The annual all-cause mortality rate for patients with
ESRD on HD is 170 deaths per 1000 at-risk patient-years.
Infection-related causes are second only to cardiovascular
events as a cause for mortality among ESRD patients when
withdrawal from dialysis is excluded.3
It is imperative to identify and mitigate infection risk in
ESRD patients on HD. Among the various HD access
routes, tunneled, cuffed catheters (TCCs) have the highest
risk of infection compared with arteriovenous ﬁstulae
(AVFs). Arteriovenous grafts (AVGs) assume an intermediate position in this unfortunate hierarchy of infection.4
Patients with TCCs had a 53% increased risk of all-cause
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mortality, 2- and 3-fold higher risk for fatal and nonfatal infections, respectively, and a 68% higher risk for hospitalization than patients with AVFs.5 Patients using AVGs
had a 38% risk for fatal infections and 16% additional
risk of mortality compared with those with AVFs. The severe consequences of different HD access-related infections warrant ongoing and comprehensive knowledge of
this ﬁeld. This review will discuss multiple HD accessrelated infections, diagnosis, and management along
with an emphasis on speciﬁc settings.
TUNNELED DIALYSIS CATHETER
Nearly 80% of patients starting HD use TCC as their ﬁrst
vascular access.1 Catheter usage rate has remained unchanged for many years. The association of TCC use and
bloodstream infections (BSIs) has been known for over
20 years.6 The catheter-related BSI (CRBSI) rate is a reportable parameter for surveillance and also a benchmark
and performance indicator for both hospitals and dialysis
units.7 The Centers for Disease Control and Prevention
suggest vascular access-related infection rates in dialysis
units to be reported as the number of events per 100/patient-months on dialysis.8 In 2014, the National Healthcare
Safety Network reported 29,516 BSIs from 6005 HD
centers.9 Nearly 75% of these infections were related
to vascular access, and 70% of all access-related
BSIs (ARBSIs) were in patients with a TCC. Overall,
pooled mean BSI and ARBSI rates per 100 central venous
catheter patient-months were 2.16 and 1.83, respectively.
Hospitalizations occurred for 25.1% of vascular access
infections and 10.8% of local access site infections with
death occurring in 1352 (0.8%) of all dialysis events.
Two percent of BSIs and 1.6% of ARBSIs resulted in fatalities. The problem of infection associated with TCC is
indisputable. The risk factors for BSI in TCC include the
duration of the catheter,10 past catheter-related bacteremia,11 left-sided internal jugular vein catheters,12 hypoalbuminemia, and immunosuppression. Surprisingly, the
human immunodeﬁciency virus infection has not been
Adv Chronic Kidney Dis. 2019;26(1):16-22
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associated with a higher risk of catheter-related bacteremia.13
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heightens the pathogenicity of various microorganisms
by allowing them to resist host defense mechanisms or
by increasing antimicrobial resistance agents. Catheters
can cause mural thrombus in the vein; a characteristic
noted to predispose to catheter colonization and infection.19 This association has led to an emphasis on preventing catheter-related thrombus as an additional mechanism
for reducing CRBSI.

MICROBIOLOGY OF ACCESS-RELATED INFECTION
The recent National Healthcare Safety Network report on
ARBSI associated with in-center HD highlights the
continued dominance of Staphylococcus aureus (S. aureus),
followed by Staphylococcus epidermidis and other
coagulase-negative staphylococci, together accounting
for nearly 56% with another 12% being gram-negative orDIAGNOSIS OF CATHETER-RELATED INFECTION
The determination of infection in patients with TCC for
ganisms. Among the S. aureus group, 40% were methicillin
dialysis is debatable. Exit-site infection and tunnel infecresistant,9 although the rate of invasive methicillinresistant S. aureus (MRSA) infections in patients on dialysis
tions are relatively easy to diagnose (Fig 1). Intravascular
is declining.14 S. aureus is known to cause high morbidity,
catheter-related infections are frequently described by
mortality, and hospitalization along with secondary metatwo terms, i.e., CRBSI and central line–associated BSI
static infections such as endocarditis, osteomyelitis, septic
(CLABSI).20 Although different, these terms are often
arthritis, epidural abscess, and cross-infection of implantused interchangeably. CRBSI is a clinical deﬁnition used
to diagnose and treat patients and requires speciﬁc laboraable cardiac devices and other intravascular devices. Dialtory testing to identify the catheter as the source of the BSI.
ysis units are a perfect setting for cross-contamination and
acquisition of multidrug-resistant (MDR) organisms. In
A CLABSI is a primary BSI in a patient with a catheter inserted within 48 hours before developing the BSI and no
a prospective cohort study of an outpatient HD unit,
other identiﬁable source of infection. CLABSI is used for
serial surveillance cultures for MDR gram-negative
bacteria, vancomycin-resistant enterococci, and MRSA in
surveillance purposes. BSIs are often secondary to other
sources not easily recogpatients undergoing chronic
nized, leading to overestiHD, nearly 28% were coloCLINICAL SUMMARY
nized with one or more
mation of the actual
MDR organisms.15 Speciincidence of CRBSI. In their
 More than two-thirds of access-related bloodstream infecmens were collected from
2009 guidelines, the Infections are due to catheter infections.
rectum, nares, and skin (a 5
tious Diseases Society of
 Management of catheter-related bloodstream infections
3 5-cm area in the jugulodiAmerica (IDSA) advocated
should be based on available access sites, patient status,
gastric and inguinal regions).
the deﬁnition of CRBSI as
and virulence of the organism.
Risk factors for colonization
“bacteremia or fungemia in
 Infection of abandoned arteriovenous grafts should be
included residence in a longa patient who has an intraincluded during the evaluation of sepsis in patients on
term facility or recent antivascular device and .1 poshemodialysis.
biotic use, both of which are
itive blood culture result
common in patients undergoobtained from the periph When feasible, the complete removal of an arteriovenous
graft is preferred.
ing HD. By four months into
eral vein; clinical manifestathe study, 40% of patients
tions of infection (e.g., fever,
had acquired at least one
chills, and/or hypotension);
MDR organism, suggesting a real problem of crossand no other apparent source for BSI (with the exception
contamination. In a prospective cohort study from Taiwan,
of the catheter).21 One of the following should be present:
a positive result of semiquantitative (115 culture forming
MRSA carriers had nearly three times higher risk of allcause mortality, ﬁve times higher risk of infection-related
units (cfu) per catheter segment) or quantitative (1102 cfu
per catheter segment) catheter culture, whereby the same
mortality, and almost three times higher risk of recurrence
organism (species) is isolated from a catheter segment
than MRSA noncarriers.16 MDR carrier states are not
benign. Preventive measures aimed at crossand a peripheral blood culture; simultaneous quantitative
contamination and colonization must be an integral part
cultures of blood with a ratio of 13:1 cfu/mL of blood (cathof infection control in dialysis units.
eter vs peripheral blood); differential time to positivity
(growth in a culture of blood obtained through a catheter
PATHOGENESIS
hub is detected by an automated blood culture system at
The cuff in a TCC impedes direct migration of organisms,
least 2 hours earlier than a culture of simultaneously
mitigating the most likely cause of infection with nontundrawn peripheral blood of equal volume).” These recomneled dialysis catheter. Direct contamination of the cathmendations are based on data from nontunneled catheters
eter or hub, hematogenous seeding, or contaminated
used in intensive care setting mainly for medication and
infusates are other possible routes of infection. Factors
ﬂuid administration or from long-term catheters used for
affecting the pathogenesis of CRBSI include, but are not
chemotherapy, total parenteral nutrition, and/or other
limited to, the catheter material and ﬁbrin sheath around
non-HD uses. This deﬁnition and workup are not suitable
the catheter17 and intrinsic virulence factors of the organfor patients receiving outpatient HD. Two signiﬁcant paism, including the extracellular polymeric substance prorameters used in the deﬁnition of CRBSI, quantitative
duced by the adherent organisms.18 Bioﬁlm formation
blood cultures and time to differential positivity, are
Adv Chronic Kidney Dis. 2019;26(1):16-22
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Figure 1. Infection of exit site and tunnel.

difﬁcult to use in outpatient dialysis centers. Positive quantitative blood cultures need a 3-fold higher count of cfu per
milliliter in the catheter hub culture than the peripheral
venous blood culture. The differential time to positivity
needs blood culture from the catheter hub to turn positive
at least 2 hours before the peripheral blood culture.22 In a
well-functioning HD catheter, blood ﬂow might dilute the
density of microorganisms in the catheter, rendering advantages of quantitative blood cultures muted. A closed
circuit-like HD tubing is not similar to unidirectional catheters used in intensive care units in which the criteria of
quantitative and differential time to positivity were based
on the IDSA guidelines. Obtaining a second peripheral
venous sample for culture is against the principle of vein
preservation for future access needs in patients on HD.
Overall, the 2009 IDSA guidelines do not address the
needs for diagnosis of CRBSI in the HD population.
Lok23 reported on the optimal methodology for diagnosis of CRBSI in patients receiving HD using a TCC.
The effort was to validate the 2009 IDSA recommendations
on the determination of CRBSI in HD patients using a
TCC, especially the use of differential time to positive
culture. In a prospective study of patients receiving HD
with a TCC in Canada, there were 178 suspected CRBSI
events in 87 patients, out of which 100 events had blood
cultures drawn when there were symptoms and signs of
infection, suggesting a CRBSI. The source of blood samples
was from the blood circuit, catheter hub, or peripheral
veins. Of these 100 events occurring in 62 patients, 55%
had no bacterial growth on blood culture. Patients had
been onantibiotics before drawing blood cultures in ﬁve
events. Twenty-seven events had growth of the same

microorganism in all the blood cultures drawn from
different sites. The average time from HD initiation to obtaining the culture was 2 hours 18 minutes. The average
transit time of culture bottles to the microbiology laboratory and start of cultivation was 5 hours 54 minutes. This
transit time might be much longer in the real-world scenario with many dialysis units often located in far-ﬂung
areas with scheduled blood sample pickups during the
day. The sensitivity and speciﬁcity of different sites of cultures were very high with no signiﬁcant difference. Cultures from the HD circuit had the highest sensitivity,
speciﬁcity, and accuracy (93.5%, 100%, and 95%, respectively). Criteria of time to positivity conﬁrming CRBSI as
per IDSA 2009 guidelines were met in less than one-third
of the events (33% arterial hub and 29% venous hub). Obtaining blood cultures within the ﬁrst 30 minutes of the
dialysis session did not improve the likelihood of positive
differential time to positivity. Only 56% of the events had
blood cultures obtained from a peripheral vein, highlighting the problem of peripheral venous access in patients with ESRD. Although the study validated the
current practice of diagnosis of CRBSI in the majority of
outpatient HD patients, the ﬁndings were unable to support the IDSA 2009 guideline recommendations, especially
in the context of the need for peripheral vein sample and
differential time to positivity. The current deﬁnition of
CRBSI is pragmatically unsuitable for the chronic HD population and is overdue for an update. Management strategies that advocate catheter removals as ﬁrst-line
management can thus promote accelerated venous access
site exhaustion. Future CRBSI deﬁnitions should incorporate objective diagnostic parameters to mitigate accelerated venous access site losses in the HD population.
MANAGEMENT OF CATHETERS IN CRBSI
The least contentious step in catheter-related infection is
the administration of antibiotics. Once a diagnosis of
CRBSI is conﬁrmed and causative organism identiﬁed,
the institution of appropriate antibiotics is recommended
along with an evaluation for metastatic infectious foci
such as endocarditis and osteomyelitis. Management of
the culprit catheter is debatable. IDSA guidelines recommend catheter removal as part of the management, especially when associated with metastatic infections, severe
sepsis, or speciﬁc virulent organisms such as S. aureus,
Pseudomonas, fungi, and mycobacteria or less virulent but
hard to eradicate organisms. In ESRD patients with catheters and uncomplicated CRBSI not due to the organisms
mentioned previously, the IDSA guidelines provide an option of not removing the catheter. Strict adherence to the
IDSA guidelines can lead to accelerated loss of venous access sites for catheter insertion, potentially expediting the
progression toward terminal access scenarios culminating
in high mortality. Several nonrandomized studies evaluating catheter exchange vs removal and delayed insertion
have been reported.24 Most of the studies were retrospective, small, with heterogeneous outcome measures, and
not an accurate comparison of catheter exchange vs catheter removal and reinsertion. Catheter salvage without
guidewire has been reported with some beneﬁts. The
Adv Chronic Kidney Dis. 2019;26(1):16-22
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need to preserve venous access has been the primary
driver for considering alternatives. Frequently, catheter
salvage is equated to access site salvage. A recent metaanalysis reviewed all studies evaluating various catheter
management strategies in the treatment of catheterrelated bacteremia.25 Studies included stable CRBSI with
three possible approaches, including antibiotic alone, antibiotic locks, and guidewire exchanges with the hypothesis
of equal cure rates with any of these options. The studies
were predominantly observational with some chart reviews unifying CRBSI deﬁnition and various treatment
cure deﬁnitions. Statistically signiﬁcant heterogeneity of
the cure proportions within each treatment group was
noted. Cure rates were not different, and follow-up time
did not affect the cure rate. Longer follow-up time did
not display larger cure proportions. After accounting for
the type of treatment, differences in cure proportions
were noted, with the highest cure for coagulase-negative
staphylococci, followed by gram-negative rod bacteremia
and S. aureus. Among S. aureus infections, guidewire exchange achieved signiﬁcantly higher cure proportion
than both systemic antibiotics and antibiotic lock solution
(odds ratio, 3.33 [95% conﬁdence interval (CI), 1.17 to 9.46;
P ¼ 0.02] and odds ratio, 4.72 [95% CI, 1.79 to 12.46;
P ¼ 0.002], respectively), but it was not compared with
catheter removal and delayed insertion. Information on
delayed metastatic infections from recurrent S. aureus
infection associated with guidewire exchange is sorely
needed.
A common fear in using guidewire exchange in infections with organisms such as S. aureus is that the catheter
goes over a part of the wire that would not have been
cleaned. Some of the currently available dialysis catheters
have an inner stylet that extends beyond the tip of the catheter and isolates the inner lumen of the catheter from the
guidewire, eliminating any contact with the new catheter
while preserving the access site. Another criticism of
guidewire exchange has been the contact of the catheter
with the tunnel, but there are techniques to create a new
tunnel and exit site while preserving the venous entry
site. The primary intention of adapting guidewire exchange is to safeguard the venous access site. A randomized controlled interventional trial comparing the effect
of guidewire exchange with catheter removal and delayed
insertion in patients with highly virulent organisms on
treatment cure rate and delayed complications is needed.
Such a study will be hard to conduct in the western hemisphere, whereas researchers from Egypt are reporting the
results of a similar study, which is likely the only randomized controlled trial in the recent era addressing this
issue.26 Each arm had 339 patients who were matched
for demographics and organism type. No statistically signiﬁcant differences were found in the catheter infectionfree survival time, recurrent CRBSI, or mortality, but as
anticipated, catheter removal with delayed insertion had
more extended hospitalizations. Information regarding
organism identiﬁcation and metastatic infection was,
however, lacking. Although small in number, six patients
in the catheter removal group had access site exhaustion
leading to the use of transhepatic, translumbar, and
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peritoneal dialysis. This subgroup is probably highly prevalent in clinical practice. Robust data on the incidence of
exhausted access sites of catheter removal and delayed
insertion are needed. Catheter management in CRBSI
thus remains a signiﬁcant unmet need of a patient on HD.
ANTIBIOTIC LOCKS AND CONNECTOR DEVICES IN
CRBSI PROPHYLAXIS
Antimicrobial lock (AML) therapy involves instillation of a
concoction of an antibiotic and an anticoagulant into the
intraluminal portion of a dialysis catheter between treatments to sterilize the interior of the catheter from the bioﬁlm. Antibiotic locks are used as part of the treatment of
CRBSI and, more controversially, as prophylaxis to prevent a CRBSI episode. Although prophylactic use of gentamicin with heparin AML is known to reduce CRBSI by
.95%, the emergence of resistant organisms has been the
primary driver for lack of consensus on its use.27 A prospective observational trial using a lower concentration
of gentamicin with citrate as anticoagulant reported a
decrease in mortality after AML (adjusted hazard ratio,
0.32; 95% CI, 0.14–0.75) with a 73% reduction in CRBSIs
in association with a decline in gentamicin resistance,
which highlights the ongoing controversy in this ﬁeld.28
Although the debate on antibiotic resistance continues,
alternative agents such as Taurolidine, ethanol, and combination concoctions including 7% sodium citrate, 0.05%
methylene blue, and 0.165% parabens, are being studied
for prophylactic use with promising results.29,30
Catheter hub colonization can be a potential source of
infection. Closed connector systems (TegoÒ) are Food
and Drug Administration–approved connector devices
for use in HD catheters.31 This device creates a mechanically and microbiologically closed system when attached
to the hub of a catheter, eliminating open catheter hubs
and lowering the chance of contamination and infection.
CUROSÒ, a 70% isopropyl alcohol–impregnated port protector, has shown signiﬁcant improvement in CLABSI rate
among oncologic patients with catheters.32 CUROSÒ is
also used in combination with TegoÒ among patients
with HD catheters. ClearguardÒ is a cap that features a
rod extending into the HD catheter hub. The rod and cap
threads are dry-coated with chlorhexidine. Once applied
like a standard catheter hub cap, chlorohexidine mixes
with catheter lock solution proximal to the clamp to kill
.99.99% of common pathogenic organisms. In an openlabeled, cluster randomized trial, ClearguardÒ showed a
signiﬁcant improvement in CRBSI in comparison with a
combination of TegoÒ and CUROSÒ among patients
with HD catheters.33 Another novel antimicrobial device
containing chlorhexidine digluconate infused into the
catheter lumen during locking has shown promising results against S. aureus in animal studies.34 These devices
and emerging advances in drug delivery along with multidrug nonantibiotic catheter lock solutions offer a ray of
hope to prevent the development of CRBSIs.
Advances in catheter-coating technology provide
another option in CRBSI prophylaxis. Nanosilver deposition over polyurethane dialysis catheters has been reported to impede adhesion of S. aureus on the surface of
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the catheters.35 The development of S. aureus bioﬁlms has
been prevented for upto 3 days using an organoselenium
compound in HD catheters in an in vivo study.36 Bismuth
coating is reported to reduce bacterial colonization of temporary nontunneled HD catheters.37 Adoption of novel
coating technology in the long-term tunneled dialysis
catheter is slow and infrequent likely due to economic
and market constraints. Large comparative clinical trials
with infectious complications as an endpoint are sorely
needed.
Infectious Complications of Arteriovenous Grafts
AVGs are second after TCCs regarding infection risk. Unlike TCCs that can be removed with a simple procedure,
AVGs, once implanted, require additional surgery, which
is generally more extensive. Frequently, a segment of
AVG adjoining the arterial anastomosis and venous anastomosis might be retained to avoid more extensive
vascular dissection and reconstruction. During a patient’s
dialysis lifetime, many AVGs are abandoned and retained.
Infections in AVG can present as clinically apparent signs
such as cellulitis, edema around the graft, erythema,
tenderness, pus, and frequently thrombosis38 (Fig 2).
Routes of infection could be direct inoculation, hematogenous spread, and/or colonization. Abandoned AVGs can
lead to signiﬁcant infectious complications, and a high degree of suspicion is warranted. Also, evidence shows that
abandoned, retained AVGs may contribute to the inﬂammatory state in association with erythropoietin resistance
in dialysis patients.39,40 In an observational report of
cultures from clots extracted during thrombectomy
procedures, signiﬁcant bacterial growth was revealed
without clinical bacteremia.39 Diagnosis of a clinically
symptomatic AVG infection is challenging. Indium uptake
scan41 and ﬂuorodeoxyglucose positron emission tomography/computed tomography42 have been reported to
identify infection in clinically asymptomatic and abandoned AVGs and further correlated with positive microbiological growth. Gram-positive organisms, especially S.
aureus, are the predominant cause of infections in
AVGs.43 Over the last decade, the use of endovascular
stents in the management of AVG dysfunction has

Figure 2. Infected arteriovenous graft with erythema over
the cannulation area.

increased. Covered stents used to treat an intragraft pseudoaneurysm were associated with subsequent graft infection compared with bare or covered stents deployed
within the graft for other reasons: 42.1% vs 18.2%
(P ¼ .011).44 The site of stent deployment is also important
with intragraft location associated with a higher incidence
of graft infection than those deployed at the venous anastomosis or outﬂow vein: 26.9% vs 6.9% (P ,.001). Management of infected graft material varies based on clinical
presentation. Total graft excision, including anastomosis
and likely arterial repair, is indicated in patients with severe sepsis or when the entire graft is bathed in pus. Subtotal graft excision involves leaving a remnant of the
oversewn small cuff of prosthetic material on an underlying patent artery. Partial graft excision is when only a
limited portion of the infected graft is removed and a
new graft is rerouted through an adjacent sterile tissue to
maintain patency of the original graft.45 The difﬁculty in
total resections could be complicated by increasing the
use of endovascular stents at the vein graft anastomosis.
Remnants of the graft material could lead to reinfection
rate as high as 15% while avoiding extensive vascular
reconstruction.46 Newer graft materials have lower infection risks, although the site of graft placement may also
affect the risk of infection.47,48 Drug-eluting AVGs are
very promising. Heparin-coated AVG is the only drugcoated AVG that is commercially available currently. Animal studies using triple antimicrobial coated AVGs have
reported a signiﬁcant reduction of infection. Although in
a nascent stage, electrospun nanoﬁber technology for
drug delivery offers novel therapeutic options.49 A study
in rabbits using a vancomycin-eluting AVG has demonstrated sustained delivery of vancomycin to the surrounding tissues.50 Future adaption of this novel technology
with a bioengineered AVG could herald a new era of
vascular access choices.
Infectious Complications of Arteriovenous Fistulas
Conventionally, AVF is considered to have a low infectious
risk with two recent meta-analyses reporting a rate of 24%4,51 and a rate of 0.018/100 access days.51 Infections
associated with AVF are generally perivascular cellulitis
with classic signs of localized erythema, swelling, and
tenderness. It is not uncommon to observe infectionassociated abnormalities such as an aneurysm with an
overlying ulcerated skin or abscess from an infected needle
puncture site. Infected ulcers overlying AVF are prone to
life-threatening hemorrhage and demands emergent surgical intervention. Needle puncture site infection has
been a major concern in buttonhole cannulations. Bacterial
colonization of the buttonhole cannulation tract may lack
classic clinical signs.52 In addition, colonization of buttonholes with S. aureus signiﬁcantly increases the likelihood of
a clinical access-related infection (4.97 event rates of
access-related infection/1000 access days). Nearly 30% of
patients with colonization also have asymptomatic bacteremia, raising the risk of endocarditis. Widespread use of
buttonhole cannulation techniques in dialysis units could
lead to S. aureus infection rates similar to TCC access.53
The problem is compounded in nocturnal home HD
Adv Chronic Kidney Dis. 2019;26(1):16-22
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patients who use buttonhole cannulation with nearly 3
times higher access-related infection than conventional
in-center HD.54 Infectious complications along with difﬁcult to achieve AVF maturations warrant a serious review
of AVF as being the most preferred HD access.
CONCLUSION
Infectious complications of dialysis access carry signiﬁcant
risk of morbidity and mortality. Arteriovenous ﬁstula continues to be the access with the least risk of infection. Catheters have the highest risk of infection with continued
controversy on the optimal management of the catheter
during a CRBSI episode. An individualized approach to
catheter management in CRBSI with careful access site
availability, to avoid exhaustion of access sites, is warranted. AVG can provide an alternative low-infection
risk access compared with TCC, but signiﬁcant infectionrelated morbidity still exists.
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